Working… Menu
Trial record 1 of 17 for:    Phasebio
Previous Study | Return to List | Next Study

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). (VANGARD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04433546
Recruitment Status : Terminated (Company no longer pursing indication)
First Posted : June 16, 2020
Last Update Posted : December 11, 2020
Information provided by (Responsible Party):
PhaseBio Pharmaceuticals Inc.

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : December 2, 2020
Actual Study Completion Date : December 2, 2020